Biotech company Electra Therapeutics (ETRA.US) IPO priced at $14-16 per share, aiming to raise $325 million.

Zhito Finance APP has learned that Electra Therapeutics, a Phase II/III biotech company focused on developing targeted anti-SIRP antibodies for immune diseases and cancer treatment, announced the terms of its initial public offering (IPO) on Monday. The company plans to offer 21.7 million shares at a price of $14-16 per share to raise $325 million. The company plans to list on the Nasdaq under the ticker symbol "ETRA".